Psoriatic arthritis (PsA) is a long-term, inflammatory disease affecting the joints and where tendons and ligaments connect to the bones. It doesn't have a cure. But a growing number of treatments can ...

Most people start a disease modifying antirheumatic drug (DMARD), such as methotrexate, soon after RA diagnosis. If you're still adjusting to a DMARD or want to better understand how it slows joint ...

DMARDs are a medication that suppresses the immune system. People may take them to slow disease progression in autoimmune or inflammatory conditions, such as different types of arthritis. Inflammation ...

Rheumatoid arthritis (RA) treatment has made major strides over the past few decades — first with the use of disease-modifying anti-rheumatic drugs (DMARDs), then with the introduction of biologic ...

DMARDs, including TNF-alpha inhibitors, may relieve pain and inflammation and help prevent joint damage from rheumatoid arthritis (RA). TNF-alpha inhibitors block TNF-alpha, which causes joint pain ...

Advances in medication have changed ankylosing spondylitis treatment and may even change the progression of the disease. That’s welcome news for many people who deal with the pain and stiffness of ...

One of the most talked about treatments for rheumatoid arthritis (RA) involves the use of disease-modifying antirheumatic drugs or DMARDs. Studies show these medications can actually halt the ...

Please provide your email address to receive an email when new articles are posted on . Maximizing the disease-modifying benefits of methotrexate is one of the core principles behind the 2021 American ...

A study looked at more than 23,600 Medicare beneficiaries with RA who had received a ≥30-day prescription of an opioid drug. Participants were grouped according to those who had been prescribed a ...

About one-third of patients prefer in-hospital administration, particularly if they are older or already make frequent visits to the hospital. Most patients with rheumatoid arthritis (RA) would prefer ...

After the first 6 months of disease-modifying antirheumatic drugs (DMARDs) use in patients with rheumatoid arthritis (RA), most very abnormal results newly seen in long-term routine laboratory ...